EGFR and head and neck squamous cell carcinoma: Recent studies investigating the use of a bispecific antibody against EGFR and HER3, MEHD7945A, demonstrated robust capability of overcoming resistance to both erlotinib and cetuximab in NSCLC and HNSCC cell models [50].